Melanoma Clinical Trials in Ohio

Showing 121-140 of 257 trials

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

Melanoma, Ocular

Delcath Systems Inc.102 participantsStarted Feb 2016

Tucson, Arizona, United States • Palo Alto, California, United States • Tampa, Florida, United States +21 more locations

COMPLETEDPhase 232 miles

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

NCT02223819

The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.

Uveal Melanoma

Columbia University34 participantsStarted Mar 2015

Miami Beach, Florida, United States • New York, New York, United States • New York, New York, United States +1 more locations

PreviousPage 7 of 13Next

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Melanoma Trials in Other Cities

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Neoadjuvant and Adjuvant Checkpoint Blockade

Other Conditions in Ohio